13.50
price up icon0.37%   0.05
after-market After Hours: 13.50
loading
Mineralys Therapeutics Inc stock is traded at $13.50, with a volume of 93,852. It is up +0.37% in the last 24 hours and down -2.74% over the past month. Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
See More
Previous Close:
$13.45
Open:
$13.48
24h Volume:
93,852
Relative Volume:
0.63
Market Cap:
$671.31M
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-9.5711
EPS:
-1.4105
Net Cash Flow:
$-97.30M
1W Performance:
-2.81%
1M Performance:
-2.74%
6M Performance:
+4.25%
1Y Performance:
+62.45%
1-Day Range:
Value
$13.41
$13.75
1-Week Range:
Value
$12.57
$14.05
52-Week Range:
Value
$5.85
$16.91

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name
Name
Mineralys Therapeutics Inc
Name
Phone
(888) 378-6240
Name
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Name
Employee
28
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
MLYS's Discussions on Twitter

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-07-23 Initiated BofA Securities Buy
Mar-07-23 Initiated Credit Suisse Outperform
Mar-07-23 Initiated Evercore ISI Outperform
Mar-07-23 Initiated Guggenheim Buy
Mar-07-23 Initiated Stifel Buy
Mar-07-23 Initiated Wells Fargo Overweight
View All

Mineralys Therapeutics Inc Stock (MLYS) Latest News

pulisher
04:06 AM

Mineralys Therapeutics to Announce Third Quarter 2024 - GlobeNewswire

04:06 AM
pulisher
04:05 AM

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 - Marketscreener.com

04:05 AM
pulisher
Nov 03, 2024

Objective long/short (MLYS) Report - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 02, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial - MSN

Nov 02, 2024
pulisher
Oct 31, 2024

Mineralys Therapeutics (NASDAQ:MLYS) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Mineralys Therapeutics : Corporate Overview October 2024 - Marketscreener.com

Oct 30, 2024
pulisher
Oct 30, 2024

Mineralys Therapeutics Advances Lorundrostat Trial Progress - TipRanks

Oct 30, 2024
pulisher
Oct 30, 2024

Mineralys Therapeutics Completes Enrollment Ahead of - GlobeNewswire

Oct 30, 2024
pulisher
Oct 30, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension - The Manila Times

Oct 30, 2024
pulisher
Oct 29, 2024

Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock - MSN

Oct 29, 2024
pulisher
Oct 24, 2024

Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances - MyChesCo

Oct 24, 2024
pulisher
Oct 23, 2024

When the Price of (MLYS) Talks, People Listen - Stock Traders Daily

Oct 23, 2024
pulisher
Oct 22, 2024

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 - The Manila Times

Oct 22, 2024
pulisher
Oct 22, 2024

Mineralys to Host Virtual KOL Event on the Unmet Medical - GlobeNewswire

Oct 22, 2024
pulisher
Oct 20, 2024

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Yahoo Finance

Oct 20, 2024
pulisher
Oct 17, 2024

Hypertension Clinical Trials 2024: FDA Approvals, Medication, - openPR

Oct 17, 2024
pulisher
Oct 17, 2024

Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail

Oct 17, 2024
pulisher
Oct 16, 2024

Mineralys Therapeutics CEO sells $206,433 in stock - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Mineralys Therapeutics CEO sells $206,433 in stock By Investing.com - Investing.com Canada

Oct 16, 2024
pulisher
Oct 16, 2024

Mineralys therapeutics CFO Adam Levy sells $146,003 in stock By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Mineralys therapeutics CFO Adam Levy sells $146,003 in stock - Investing.com

Oct 16, 2024
pulisher
Oct 15, 2024

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,271 Shares - GuruFocus.com

Oct 15, 2024
pulisher
Oct 15, 2024

Insider Sale: CFO Adam Levy Sells Shares of Mineralys Therapeuti - GuruFocus.com

Oct 15, 2024
pulisher
Oct 15, 2024

Adam Scott Levy Sells 10,757 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock - MarketBeat

Oct 15, 2024
pulisher
Oct 12, 2024

(MLYS) Trading Report - Stock Traders Daily

Oct 12, 2024
pulisher
Oct 06, 2024

Mineralys Therapeutics to Unveil First Quarter Financial Results - MSN

Oct 06, 2024
pulisher
Oct 02, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc.MLYS - cnhinews.com

Oct 02, 2024
pulisher
Oct 01, 2024

When (MLYS) Moves Investors should Listen - Stock Traders Daily

Oct 01, 2024
pulisher
Oct 01, 2024

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Bought by Nantahala Capital Management LLC - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

Driehaus Capital Management LLC Increases Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug Trial - MSN

Sep 30, 2024
pulisher
Sep 29, 2024

Mineralys Therapeutics to Speak at Wells Fargo Healthcare Conference - MSN

Sep 29, 2024
pulisher
Sep 28, 2024

Blue Owl Capital Holdings LP Has $5.27 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat

Sep 28, 2024
pulisher
Sep 27, 2024

MLYSMineralys Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Sep 27, 2024
pulisher
Sep 25, 2024

Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Trial - TipRanks

Sep 25, 2024
pulisher
Sep 25, 2024

Mineralys Therapeutics completes target enrollment for Advance-HTN Trial - TipRanks

Sep 25, 2024
pulisher
Sep 25, 2024

Mineralys Therapeutics, Inc. Completes Target Enrollment in Pivotal Advance-Htn Trial of Lorundrostat for the Treatment of Hypertension - Marketscreener.com

Sep 25, 2024
pulisher
Sep 25, 2024

Mineralys Therapeutics Completes Target Enrollment in - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension - StockTitan

Sep 25, 2024
pulisher
Sep 24, 2024

Goldman starts Mineralys at buy, cites upcoming drug data - MSN

Sep 24, 2024
pulisher
Sep 24, 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mineralys Therapeutics, Inc. (MLYS) and Encourages Shareholders to Learn More About the Investigation - AccessWire

Sep 24, 2024
pulisher
Sep 24, 2024

American Century Companies Inc. Buys 23,170 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Sold by Adams Street Partners LLC - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Mineralys Therapeutics, Inc. (MLYS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire

Sep 23, 2024
pulisher
Sep 22, 2024

MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire

Sep 22, 2024
pulisher
Sep 21, 2024

MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm! - Kilgore News Herald

Sep 21, 2024
pulisher
Sep 21, 2024

Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up to $11.69 - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

(MLYS) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Sep 20, 2024
pulisher
Sep 20, 2024

Bronstein, Gewirtz & Grossman, LLC Is Investigating Mineralys Therapeutics, Inc. (MLYS) And Encourages Shareholders to Connect - AccessWire

Sep 20, 2024
pulisher
Sep 18, 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mineralys Therapeutics, Inc. (MLYS) and Encourages Investors to Learn More About the Investigation - AccessWire

Sep 18, 2024
pulisher
Sep 17, 2024

Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning (NASDAQ:MLYS) - Seeking Alpha

Sep 17, 2024

Mineralys Therapeutics Inc Stock (MLYS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$19.96
price up icon 5.11%
$75.75
price down icon 0.50%
$376.80
price up icon 0.74%
$53.54
price down icon 2.00%
$207.25
price up icon 1.49%
$108.97
price down icon 2.25%
Cap:     |  Volume (24h):